Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $163,400.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the completion of the sale, the insider now owns 134,021 shares in the company, valued at $2,189,903.14. The trade was a 6.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $14.59 on Friday. The firm’s 50 day simple moving average is $16.48 and its 200-day simple moving average is $16.41. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09. The firm has a market cap of $1.92 billion, a PE ratio of -9.54 and a beta of 1.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of CNTA. Jane Street Group LLC acquired a new stake in Centessa Pharmaceuticals during the 3rd quarter worth about $2,834,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals during the third quarter valued at $1,609,000. State Street Corp acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $777,000. Ally Bridge Group NY LLC purchased a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $4,951,000. Finally, Lord Abbett & CO. LLC acquired a new position in Centessa Pharmaceuticals during the third quarter worth $4,305,000. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CNTA. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday. Finally, TD Cowen began coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.